drugset / Trial / NCT06766916

Crisugabalin for Radiotherapy-Related Neuropathic Pain

NCT06766916

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate whether Crisugabalin has similar efficacy compared to Pregabalin in reducing radiotherapy-related neuropathic pain (RRNP) in patients with head and neck cancers.

Timeline

Start
2025-05-07
Primary completion
2026-11-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK16149 Unknown 60 mg Oral
Comparator Pregabalin Small molecule 300 mg Oral

Indications